dermtech is a molecular diagnostic dermatology company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. dermtech operates a clia (clinical laboratory improvement amendments) licensed laboratory located at the company’s la jolla, ca headquarters. dermtech’s technology allows for the analysis of skin biopsy samples collected non-invasively using an adhesive patch. current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. dermtech’s pigmented lesion assay (pla) provides physicians with a non-invasive option for the biopsy of clinically atypical pigmented lesions using an adhesive patch rather than a scalpel. dermtech provides highly accurate, objective information to the physician to improve patient care and comfort and reduce costs. the pla is used for the detection of melanoma in at
Company profile
Ticker
DMTK, DMTKW
Exchange
Website
CEO
John D. Dobak
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Constellation Alpha Capital Corp.
SEC CIK
Corporate docs
Subsidiaries
DermTech Operations, Inc. ...
DMTK stock data
Latest filings (excl ownership)
8-K
Dermtech to Explore Strategic Alternatives and Implement Restructuring Plan
18 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Dermtech Reports Fourth-quarter 2023 Financial Results
29 Feb 24
8-K
Dermtech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
31 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Dermtech Reports Third-quarter 2023 Financial Results
2 Nov 23
8-K
Dermtech Appoints Mark Aguillard As Chief Commercial Officer
11 Sep 23
S-8
Registration of securities for employees
7 Aug 23
Transcripts
DMTK
Earnings call transcript
2023 Q4
29 Feb 24
DMTK
Earnings call transcript
2023 Q3
2 Nov 23
DMTK
Earnings call transcript
2023 Q2
3 Aug 23
DMTK
Earnings call transcript
2023 Q1
4 May 23
DMTK
Earnings call transcript
2022 Q4
2 Mar 23
DMTK
Earnings call transcript
2022 Q3
3 Nov 22
DMTK
Earnings call transcript
2022 Q2
9 Aug 22
DMTK
Earnings call transcript
2022 Q1
4 May 22
DMTK
Earnings call transcript
2022 Q1
3 May 22
DMTK
Earnings call transcript
2021 Q4
2 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.70 mm | 40.70 mm | 40.70 mm | 40.70 mm | 40.70 mm | 40.70 mm |
Cash burn (monthly) | 1.85 mm | 4.86 mm | 6.60 mm | 9.41 mm | 6.35 mm | 7.13 mm |
Cash used (since last report) | 12.70 mm | 33.26 mm | 45.23 mm | 64.43 mm | 43.48 mm | 48.81 mm |
Cash remaining | 28.00 mm | 7.43 mm | -4.54 mm | -23.73 mm | -2.78 mm | -8.11 mm |
Runway (months of cash) | 15.1 | 1.5 | -0.7 | -2.5 | -0.4 | -1.1 |
Institutional ownership, Q3 2023
24.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 77 |
Opened positions | 7 |
Closed positions | 14 |
Increased positions | 18 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 10.16 bn |
Total shares | 8.63 mm |
Total puts | 161.10 k |
Total calls | 228.90 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 2.72 mm | $3.91 bn |
Van Herk Investments B.V. | 1.56 mm | $4.01 mm |
Vanguard | 1.21 mm | $1.74 bn |
BLK Blackrock | 435.74 k | $627.46 mm |
Hongkou Capital | 402.53 k | $579.64 mm |
Geode Capital Management | 281.32 k | $405.22 mm |
King Luther Capital Management | 204.48 k | $294.46 mm |
White Pine Capital | 197.39 k | $284.25 mm |
MS Morgan Stanley | 156.29 k | $225.06 mm |
Susquehanna International | 137.52 k | $198.03 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Mar 24 | Sun Kevin M | Common Stock | Payment of exercise | Dispose F | No | No | 0.7 | 445 | 311.50 | 274,606 |
5 Mar 24 | Sun Kevin M | Common Stock | Payment of exercise | Dispose F | No | No | 0.88 | 2,531 | 2.23 k | 272,551 |
5 Mar 24 | Sun Kevin M | Common Stock | Payment of exercise | Dispose F | No | No | 0.88 | 2,237 | 1.97 k | 275,082 |
5 Mar 24 | Sun Kevin M | Common Stock | Payment of exercise | Dispose F | No | No | 0.88 | 180 | 158.40 | 277,319 |
5 Mar 24 | Ramin Akhavan | Common Stock | Payment of exercise | Dispose F | No | No | 0.88 | 1,989 | 1.75 k | 132,170 |
5 Mar 24 | Ramin Akhavan | Common Stock | Payment of exercise | Dispose F | No | No | 0.88 | 1,758 | 1.55 k | 134,159 |
5 Jan 24 | Ramin Akhavan | Common Stock | Payment of exercise | Dispose F | No | No | 1.5 | 3,202 | 4.80 k | 135,917 |
News
What Analysts Are Saying About DermTech Stock
19 Apr 24
Lake Street Downgrades DermTech to Hold, Announces $0.63 Price Target
19 Apr 24
BTIG Downgrades DermTech to Neutral
19 Apr 24
DermTech Intends To Continue Laboratory Operations During Strategic Review
18 Apr 24
DermTech To Seek Strategic Alternatives; Plans Restructuring Actions That Will Result In Workforce Reduction Of ~100 Employees, Or 56% Of Workforce
18 Apr 24
Press releases
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
18 Apr 24
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
8 Mar 24
DermTech Reports Fourth-Quarter 2023 Financial Results
29 Feb 24
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
13 Feb 24